Press Release

Glythera appoints Chief Scientific Officer and strengthens SAB

Dr Robert Lutz appointed as CSO to support development of next-generation PermaLink® Antibody Drug Conjugates Dr Jon Roffey appointed to Scientific Advisory Board Newcastle, UK, 17th January, 2018: Glythera Limited (Glythera), the next generation antibody drug conjugate (ADC) development company, is pleased to announce the appointment of Dr Robert Lutz as Chief Scientific Officer. Dr Lutz will lead the advancement of Glythera’s portfolio of Antibody Drug Conjugates (ADCs) in the treatment of difficult-to-treat cancers. In addition, Glythera has appointed Dr…

Read more>>

Positive Outcome of Proof-of-Concept Study with Glythera and Follow on Drug Development Partnership

Successful proof-of-concept study leads to Affimer drug conjugate development partnership Affimers shown to have key technical benefits for drug conjugates Drug conjugate market expected to be worth $14.6bn by 2030 Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that its initial study with Glythera Limited, the developer of next generation antibody drug conjugates, has concluded successfully.  Following this study the two companies have agreed the terms of a licensing deal which will allow…

Read more>>

Glythera licenses novel payload class from Cancer Research UK for the development of next-generation antibody drug conjugates

Glythera gains exclusive access to Cancer Research UK’s novel CDK11 inhibitor programme for the development of ADCs conjugated using its highly stable conjugation platform, PermaLink® Glythera will generate multiple ADCs with improved therapeutic index directed towards antigens specific to difficult-to-treat tumours, combining CDK11 inhibitors with its growing in-house antibody portfolio Glythera Limited (Glythera), the next generation antibody drug conjugate (ADC) development company, and Cancer Research UK* today announced an agreement giving Glythera exclusive, worldwide rights to the charity’s novel CDK11…

Read more>>

 Last ›

Page 1 of 11